Terms: = Lung cancer AND CBFA2T3, ETO2, 863, ENSG00000129993, ZMYND4, MTGR2, MTG16 AND Treatment
42 results:
1. The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China.
Dai Z; Xu J; Chang F; Zhou W; Ren T; Qiu J; Lu Y; Lu Y
Front Public Health; 2024; 12():1333487. PubMed ID: 38699428
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic implications of neutrophil-to-lymphocyte ratio in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy: A multicenter, real-world study.
Bi H; Ren D; Xiao Y; Zhou Y; Yi B; Han W; Shao Y; Wang J; Zhang C; Wang H
Thorac Cancer; 2024 Mar; 15(7):559-569. PubMed ID: 38294282
[TBL] [Abstract] [Full Text] [Related]
3. Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma.
Dumoulin DW; Douma LH; Hofman MM; van der Noort V; Cornelissen R; de Gooijer CJ; Burgers JA; Aerts JGJV
Lung Cancer; 2024 Jan; 187():107440. PubMed ID: 38104353
[TBL] [Abstract] [Full Text] [Related]
4. Epidemiology and survival outcomes of synchronous and metachronous brain metastases: a retrospective population-based study.
Jiang K; Parker M; Materi J; Azad TD; Kamson DO; Kleinberg L; Ye X; Rincon-Torroella J; Bettegowda C
Neurosurg Focus; 2023 Aug; 55(2):E3. PubMed ID: 37527669
[TBL] [Abstract] [Full Text] [Related]
5. Establishment and visualization of a model based on high-resolution CT qualitative and quantitative features for prediction of micropapillary or solid components in invasive lung adenocarcinoma.
Dong H; Wang X; Qiu Y; Lou C; Ye Y; Feng H; Ye X; Chen D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10519-10530. PubMed ID: 37289235
[TBL] [Abstract] [Full Text] [Related]
6. Diet as a Factor Supporting lung cancer treatment-A Systematic Review.
Polański J; Świątoniowska-Lonc N; Kołaczyńska S; Chabowski M
Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986207
[TBL] [Abstract] [Full Text] [Related]
7. DADFN: dynamic adaptive deep fusion network based on imaging genomics for prediction recurrence of lung cancer.
Jia L; Wu W; Hou G; Zhang Y; Zhao J; Qiang Y; Wang L
Phys Med Biol; 2023 Mar; 68(7):. PubMed ID: 36867882
[No Abstract] [Full Text] [Related]
8. Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell lung cancer With Implications for Regulatory and Health Technology Assessment.
Ramagopalan SV; Popat S; Gupta A; Boyne DJ; Lockhart A; Hsu G; O'Sullivan DE; Inskip J; Ray J; Cheung WY; Griesinger F; Subbiah V
JAMA Netw Open; 2022 Nov; 5(11):e2239874. PubMed ID: 36326765
[TBL] [Abstract] [Full Text] [Related]
9. The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non-small cell lung cancer: A real-world study.
Feng Y; Huang L; Zhu H; Tang L; Hu X; Shi Y
Thorac Cancer; 2022 Sep; 13(18):2641-2649. PubMed ID: 36082809
[TBL] [Abstract] [Full Text] [Related]
10. Access to Care Metrics in Stage I lung cancer: Improved Access Is Associated With Improved Survival.
Heiden BT; Eaton DB; Chang SH; Yan Y; Schoen MW; Patel MR; Kreisel D; Nava RG; Samson P; Meyers BF; Kozower BD; Puri V
Ann Thorac Surg; 2022 Nov; 114(5):1810-1815. PubMed ID: 35724700
[TBL] [Abstract] [Full Text] [Related]
11. Improving Outcomes in NSCLC: Optimum Dose Fractionation in Radical Radiotherapy Matters.
Brada M; Forbes H; Ashley S; Fenwick J
J Thorac Oncol; 2022 Apr; 17(4):532-543. PubMed ID: 35092841
[TBL] [Abstract] [Full Text] [Related]
12. [Affinity chromatography based phosphoproteome research on lung cancer cells and its application].
Zhang B; Wang C; Guo M; Xiao H
Se Pu; 2021 Jan; 39(1):77-86. PubMed ID: 34227361
[TBL] [Abstract] [Full Text] [Related]
13. Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study.
Garon EB; Winfree KB; Molife C; Cui ZL; Arriola E; Levy B; Mekhail T; Pérol M
Support Care Cancer; 2021 Jan; 29(1):117-125. PubMed ID: 32318871
[TBL] [Abstract] [Full Text] [Related]
14. A quantitative imaging biomarker for predicting disease-free-survival-associated histologic subgroups in lung adenocarcinoma.
Lu L; Wang D; Wang L; E L; Guo P; Li Z; Xiang J; Yang H; Li H; Yin S; Schwartz LH; Xie C; Zhao B
Eur Radiol; 2020 Jul; 30(7):3614-3623. PubMed ID: 32086583
[TBL] [Abstract] [Full Text] [Related]
15. Microwave ablation or plus monochemotherapy in elderly advanced non-small-cell lung cancer patients.
Wei Z; Li Q; Ye X; Yang X; Huang G; Li W; Wang J; Han X
Minim Invasive Ther Allied Technol; 2021 Apr; 30(2):106-114. PubMed ID: 31621453
[TBL] [Abstract] [Full Text] [Related]
16. A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients.
Tani T; Naoki K; Yasuda H; Arai D; Ishioka K; Ohgino K; Yoda S; Nakayama S; Satomi R; Terai H; Ikemura S; Sato T; Soejima K
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1065-1071. PubMed ID: 31493177
[TBL] [Abstract] [Full Text] [Related]
17. PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin
Reinmuth N; Bryl M; Bondarenko I; Syrigos K; Vladimirov V; Zereu M; Bair AH; Hilton F; Liau K; Kasahara K
BioDrugs; 2019 Oct; 33(5):555-570. PubMed ID: 31338773
[TBL] [Abstract] [Full Text] [Related]
18. Time to initial cancer treatment in the United States and association with survival over time: An observational study.
Khorana AA; Tullio K; Elson P; Pennell NA; Grobmyer SR; Kalady MF; Raymond D; Abraham J; Klein EA; Walsh RM; Monteleone EE; Wei W; Hobbs B; Bolwell BJ
PLoS One; 2019; 14(3):e0213209. PubMed ID: 30822350
[TBL] [Abstract] [Full Text] [Related]
19. Estimation of Future cancer Burden Among Rescue and Recovery Workers Exposed to the World Trade Center Disaster.
Singh A; Zeig-Owens R; Moir W; Hall CB; Schwartz T; Vossbrinck M; Jaber N; Webber MP; Kelly KJ; Ortiz V; Koffler E; Prezant DJ
JAMA Oncol; 2018 Jun; 4(6):828-831. PubMed ID: 29710126
[TBL] [Abstract] [Full Text] [Related]
20. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and treatment of cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A
Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701
[TBL] [Abstract] [Full Text] [Related]
[Next]
